Screen whether your catheter shaft program should start with braid, coil, or hybrid reinforcement, then use the report below to turn the result into RFQ inputs, evidence requests, and transition-zone controls.
The conclusions below separate tool output, evidence, limits, and next action so the page supports both immediate screening and buyer-side decision making.
Evidence: Braid favors torsional response and push; coil favors bend recovery and kink resistance; hybrid designs are justified when both requirements matter in different shaft zones.
Buyer action: Use the tool to identify the first feasible architecture, then ask the CDMO for zone-by-zone evidence instead of accepting one generic shaft claim.
Evidence: ISO 10555-1 covers general intravascular catheter requirements, but the exact burst, tensile, coating, kink, and simulated-use evidence depends on the device and application.
Buyer action: Convert the recommendation into a verification matrix before freezing drawings or prototype acceptance criteria.
Evidence: The extra reinforcement interface can create stiffness jumps, poor polymer wet-out, and hidden inspection gaps around cut wire ends and reflow windows.
Buyer action: Ask for transition-zone microscopy, dimensional maps, bend/kink observations, and lot-level reflow records before pilot lot approval.
Evidence: FDA QMSR became effective February 2, 2026 and incorporates ISO 13485:2016 into U.S. device quality-system expectations.
Buyer action: Supplier selection should include document control, process validation handoff, inspection traceability, and change-control evidence, not only sample photos.
Use torque, flexibility, kink, and wall constraints to narrow braid, coil, or hybrid direction.
Share OD, ID, usable length, zone map, liner, jacket, wire material, PIC or pitch, and target application.
Request inspection method, process records, transition-zone proof, and worst-case sample rationale.
Turn feasibility data into drawing limits, CTQ controls, and IQ/OQ/PQ handoff assumptions.
Send the shaft zone map, OD/ID targets, wall target, liner, jacket, reinforcement choice, and hardest failure mode so an engineer can pressure-test the architecture before pilot lots.
Use this matrix to identify which evidence to request from a CDMO. Numeric bands are early screening ranges, not drawing tolerances or regulatory acceptance criteria.
Interwoven wire mesh for torque response, pushability, and hoop support when distal bend demands are moderate.
Helical wire support for flexible tracks, kink recovery, and lumen preservation where 1:1 torque is less important.
Zone-specific construction for conflicting proximal push, torque, distal softness, and kink recovery requirements.
These are sourcing-screening ranges derived from common reinforced catheter shaft feasibility discussions. Verify all dimensions, test methods, and acceptance limits against your device-specific drawing and risk file.
Trigger: Dense braid plus coil sections can trap air or leave local under-bonded jacket zones after reflow.
Mitigation: Request cross-section microscopy, reflow recipe limits, liner surface-prep assumptions, and bend-after-aging observations.
Trigger: A proximal braid-to-distal coil change can localize bending stress at the interface.
Mitigation: Use tapered jacket durometers, controlled overlap, and a documented transition inspection plan.
Trigger: Long, flexible coil sections can elongate under retrieval or delivery load if no tension member is defined.
Mitigation: Confirm tensile acceptance criteria and consider longitudinal support wires or fibers where retrieval load matters.
Trigger: Hydrophilic, PTFE, silicone, or other low-friction surfaces can change friction, particulate, and labeling evidence needs.
Mitigation: Separate base-shaft feasibility from final coating strategy and align with application-specific FDA guidance.
Public standards and FDA pages support the regulatory and quality-system framing. Shaft-wall bands and architecture tradeoffs are feasibility-screening assumptions that must be confirmed with supplier-specific process data.
Date Marker
Date of entry May 29, 2024; checked July 18, 2026
How It Is Used
Confirms U.S. recognition of ISO 10555-1 third edition 2023-11 for sterile, single-use intravascular catheter general requirements.
Date Marker
Third edition published November 2023; checked July 18, 2026
How It Is Used
Defines the general scope for intravascular catheters supplied sterile and intended for single use.
Date Marker
Effective February 2, 2026; checked July 18, 2026
How It Is Used
Frames why CDMO process records, traceability, validation transfer, and supplier quality controls affect sourcing decisions.
Date Marker
Issued October 10, 2019; checked July 18, 2026
How It Is Used
Supports surface-risk discussion for catheter systems used in neurovascular, coronary, and peripheral vasculature.
| Source | Date Marker | How It Is Used |
|---|---|---|
| FDA recognized consensus standard 6-499 | Date of entry May 29, 2024; checked July 18, 2026 | Confirms U.S. recognition of ISO 10555-1 third edition 2023-11 for sterile, single-use intravascular catheter general requirements. |
| ISO 10555-1:2023 catalog page | Third edition published November 2023; checked July 18, 2026 | Defines the general scope for intravascular catheters supplied sterile and intended for single use. |
| FDA Quality Management System Regulation | Effective February 2, 2026; checked July 18, 2026 | Frames why CDMO process records, traceability, validation transfer, and supplier quality controls affect sourcing decisions. |
| FDA lubricious coating guidance | Issued October 10, 2019; checked July 18, 2026 | Supports surface-risk discussion for catheter systems used in neurovascular, coronary, and peripheral vasculature. |
Share your architecture-screen result, shaft zone map, OD/ID, liner, jacket, reinforcement details, prototype quantity, and hardest CTQ. We will help translate it into a manufacturability review.